Co-founded by Drs. Brett Finlay and Bill Mohn at University of British Columbia in 2015, Microbiome Insights is in microbiome testing and bioinformatic analysis.
The advisory services and financial assistance from the government of Canada, through NRC IRAP, will help the company expand in a new direction, continuing to develop tools for use in clinical settings as new data emerge on the gut microbiome and health.
The primary aim of the company's personal health platform is to help address the challenges both healthcare practitioners and individuals face in the management of chronic disease.
Microbiome monitoring in those with chronic disease may provide a tool for assessing response to therapies or to various lifestyle changes (including diet), particularly when integrated with robust research findings and ongoing data collection.
Microbiome Insights's new testing platform will be aimed at health practitioners helping individuals who live with inflammatory bowel disease.
The efforts are led by Nataša Jovic, MBA, who brings to the company twenty years of experience in therapeutic and diagnostic commercialisation.
Microbiome Insights is currently exploring opportunities to commercialize its platform of microbiome tests for healthcare practitioners through research collaborations and distribution or joint commercialisation efforts.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007